Company profile
Alvotech
NASDAQ:ALVOBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ADALIMUMAB | phase3 | — | 59 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05632211 | phase1 | completed | 2022-12-16 | 2023-10-03 | Alvotech Swiss AG | A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants |
| NCT05126784 | phase1 | completed | 2022-06-29 | 2023-10-16 | Alvotech Swiss AG | AVT03 With Prolia in Healthy Male Subjects |
| NCT05876949 | phase1 | completed | 2023-07-21 | 2024-04-15 | Alvotech Swiss AG | AVT03 With Xgeva in Healthy Male Subjects |
| NCT05155293 | phase3 | completed | 2022-06-28 | 2023-11-17 | Alvotech Swiss AG | Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) |
| NCT07489131 | phase3 | recruiting | 2026-04-22 | 2027-07-01 | Alvotech Swiss AG | Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 761299 | BLA | Alvotech USA Inc. | ||||
Loading… | ||||||
| BLA 761343 | BLA | Alvotech USA Inc. | ||||
Loading… | ||||||